Patent US4097602A successfully refreshed from Google Patents.
US4097602A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting blood platelet aggregation
Assignee: Thomas Jefferson University
•
Filing: 1976-08-24
•
Granted: 1978-06-27
•
Expires: 1996-08-24
Abstract
Abstract A method for inhibiting blood platelet aggregation by the oral or parenteral administration to a mammal of all cis-8,11,14-eicosatrienoic acid, a compound having the formula: ##STR1## Also disclosed are other fatty acids exhibiting blood platelet aggregation inhibition properties.
Inventors
- 👤 Melvin J. Silver
- 👤 John Bryan Smith
- 👤 Carol M. Ingerman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:54
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
37 words
A method for inhibiting blood platelet aggregation comprising administrating to an individual disposed toward undesirable blood platelet aggregation from about 5-400 mg/kg of body weight of 8,11,14-eicosatrienoic acid, the ester thereof or a pharmaceutical acceptable salt thereof.
Claim 2
Independent Claim
37 words
A method for inhibiting blood platelet aggregation comprising administrating to an individual disposed toward undesirable blood platelet aggregation from about 5-400 mg/kg of body weight of 8,11,14-eicosatrienoic acid, the ester thereof or a pharmaceutical acceptable salt thereof.
Claim 3
Dependent Claim
13 words
A method according to claim 1 wherein the mode of administration is oral.
Claim 4
Dependent Claim
13 words
A method according to claim 1 wherein the mode of administration is parenteral.
Claim 5
Dependent Claim
21 words
A method according to claim 1 wherein the amount of said acid administered is 100 mg. per kg. of body weight.
Claim 6
Independent Claim
37 words
A method for inhibiting blood platelet aggregation comprising administering to an individual disposed toward undesirable blood platelet aggregation from about 5-400 mg/kg of body weight of 11,14,17-eicosatrienoic acid, the ester thereof or a pharmaceutical acceptable salt thereof.
Claim 7
Independent Claim
37 words
A method for inhibiting blood platelet aggregation comprising administering to an individual disposed toward undesirable blood platelet aggregation from about 5-400 mg/kg of body weight of 11,14,17-eicosatrienoic acid, the ester thereof or a pharmaceutical acceptable salt thereof.
Claim 8
Dependent Claim
13 words
A method according to claim 5 wherein the mode of administration is oral.
Claim 9
Dependent Claim
13 words
A method according to claim 5 wherein the mode of administration is parenteral.
Claim 10
Dependent Claim
21 words
A method according to claim 5 wherein the amount of said acid administered is 100 mg. per kg. of body weight.
Claim 11
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 5,8,11,14,17-eicosapentaenoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 12
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 5,8,11,14,17-eicosapentaenoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 13
Dependent Claim
26 words
The method according to claim 9 wherein the concentration range of said acid employed is from about 0.05mM to about 0.5mM per liter of platelet-rich plasma.
Claim 14
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 11,14,17-eicosatrienoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 15
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 11,14,17-eicosatrienoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 16
Dependent Claim
26 words
The method according to claim 11 wherein the concentration range of said acid employed is from about 0.05mM to about 0.5mM per liter of platelet-rich plasma.
Claim 17
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 8,11,14-eicosatrienoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 18
Independent Claim
33 words
A method for inhibiting blood platelet aggregation by adding to a platelet-rich plasma an effective amount, to essentially inhibit platelet aggregation, of 8,11,14-eicosatrienoic acid or pharmaceutically acceptable salts or lower alkyl esters thereof.
Claim 19
Dependent Claim
26 words
A method according to claim 13 wherein the concentration range of said acid employed is from about 0.05mM to about 0.5mM per liter of platelet-rich plasma.
Claim 20
Independent Claim
40 words
A method for inhibiting blood platelet aggregation comprising administering to an individual disposed toward undesirable blood platelet aggregation an effective amount, to essentially inhibit platelet aggregation, of 5,8,11,14,17-eicosapentaenoic acid, a lower alkyl ester thereof or a pharmaceutical acceptable salt thereof.
Claim 21
Independent Claim
40 words
A method for inhibiting blood platelet aggregation comprising administering to an individual disposed toward undesirable blood platelet aggregation an effective amount, to essentially inhibit platelet aggregation, of 5,8,11,14,17-eicosapentaenoic acid, a lower alkyl ester thereof or a pharmaceutical acceptable salt thereof.
References Cited (Backward Citations)
GB1082624A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-06-26 | 1981-12-26 | 1982-06-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-06-26 | 1985-12-26 | 1986-06-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-06-26 | 1989-12-26 | 1990-06-27 | $7700.00 | Window Closed / Lapsed |